

Post Authorisation Assessments

Marbodug 20 mg/ml Solution for Injection for Cattle and Pigs Vm 34534/5013

19 January 2025 C E 04 May 2024 S a su 27 March 2024 U su 11 January 2023 U	B QRD templates. Change of name of the MAH from Emdoka byba to Emdoka. Submission of an updated Ph. Eur. CEP from an already pproved manufacturer for a non-sterile: – active ubstance. (NI) Ipdated CEP submitted for the manufacture of an active ubstance. (GB) Ipdated certificate of suitability from an already pproved manufacturer.
E 04 May 2024 S al st 27 March 2024 U st 11 January 2023 U	mdoka. Submission of an updated Ph. Eur. CEP from an already pproved manufacturer for a non-sterile: – active ubstance. (NI) updated CEP submitted for the manufacture of an active ubstance. (GB) updated certificate of suitability from an already
27 March 2024 U st 11 January 2023 U	pproved manufacturer for a non-sterile: – active ubstance. (NI) Ipdated CEP submitted for the manufacture of an active ubstance. (GB) Ipdated certificate of suitability from an already
sı 11 January 2023 U	ubstance. (GB) Ipdated certificate of suitability from an already
,	
a	
	pdated certificate of suitability from an already pproved manufacturer.
pi fc	Change in the invented name of the veterinary medicinal roduct from Marbocare 20 mg/ml Solution for Injection or Cattle and Pigs to Marbodug 20 mg/ml Solution for njection for Cattle and Pigs in UK and IE.
C G P U 21 C W Y	ntroduction of a new pharmacovigilance system. Change in distributor details from Animalcare Ltd, 10 Great North Way, York Business Park, Nether Poppleton, York, YO26 6RB to DUGV (UK) Limited, Inion House, 111 New Union Street, Coventry, CV1 NT. Change of MAH, from Animalcare Ltd, 10 Great North Vay, York Business Park, Nether Poppleton, York, O26 6RB to Emdoka bvba, John Lijsenstraat 16, 3-2321 Hoogstraten, Belgium.
sı aı S	Deletion of a non-significant parameter of an active ubstance used in the manufacturing process of the ctive substance. Submission of a new Ph. Eur. certificate of suitability for n active substance from an already approved nanufacturer.
sy C pl C e	Change in the QPPV of an existing pharmacovigilance ystem as described in the DDPS. Change in the contact details of the QPPV of an existing harmacovigilance system as described in the DDPS. Change of the back-up procedure of the QPPV of an xisting pharmacovigilance system as described in the DDPS.
	change of RMS from UK to IE.
•	enewal – UK as RMS.

26 February 2015	Change in distributor details.
08 August 2013	Change in the address of the Marketing Authorisation
	Holder and change to the QPPV contact details.